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Abnormalities in the function of the stomach in patients with long-standing diabetes
mellitus, usually insulin-dependent, may provide difficult management problems. There is a
reduced frequency of peptic ulcer disease in diabetics. Gastric atrophy, often with parietal cell
antibodies, is common and the frequency of pernicious anemia with its expected intrinsic fac-
tor antibodies is increased. Gastric analysis results have been conflicting but generally suggest
that long-standing diabetics have lower acid levels than normals, possibly secondary to vagal
neuropathy. Gastric atony occurring in a small but sugnificant number of patients with long-
standing insulin-dependent diabetes, usually with a clinically apparent peripheral neuropathy,
has been associated with upper abdominal discomfort, vomiting, and a clinical picture of
gastric outlet obstruction. Various degrees of subclinical delays in gastric emptying are prob-
ably present in many asymptomatic patients and, indeed, are underemphasized contributors to
poor control of blood sugar levels. Studies utilizing radioactive-labeled physiological meals
have demonstrated abnormalities in the gastric emptying of solids, in particular, and
sometimes liquids in the latter stages of the disease. Metoclopramide, a dopamine antagonist,
which stimulates upper gastrointestinal smooth musculature, results in accelerated gastric
emptying; clinical trials have shown that it is capable of alleviating symptoms related to
diabetic gastroparesis and with its recent approval and release in this country, it promises im-
proved management of this entity. Another agent, domperidone, a selective peripheral
dopamine antagonist with no appreciable side effects, is in this country an investigational
drug which has shown clinical efficacy in Europe in improving gastric stasis syndromes.
GASTRIC EMPTYING IN PATIENTS WITH DIABETES MELLITUS
In the pre-insulin era, diabetic gastroparesis was of little interest and the literature
is devoid of any mention of that particular neuropathy. Gastric retention in diabetes
was first noted by Boas in 1925 [11 and the radiologic picture was described by Fer-
roir, who conducted the first thorough study of the stomach in diabetics in Paris in
1937 [2]. Thefocus was on the hypochlorhydria, which was foundin 60 percent of26
patients undergoing gastric analysis. By the use of the then relatively new barium
meal study, he described the following abnormalities: "X-ray examination showed
that in diabetics, the stomach is generally very chronic, but its motor responses are
weaker than normal: contractions are slow, lack vigor and die out quickly. Not in-
frequently, pyloric incompetence may be found with a hypotonic pyloric sphincter
producing rapid evacuation in most cases. Although insulin by itself cannot restore
in diabetics the level ofsecretion that is responsible for the healthy subject, it never-
theless alleviates secretory and motor abnormalities even without resulting in
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hypoglycemia" [2]. The first detailed descriptions of gastric retention secondary to
diabetic visceral neuropathy was by Rundles in 1945 [3]. The term "gastroparesis
diabeticorum" was coined by Kassander in 1958 where he also indicated that this
syndrome could be present in relatively asymptomatic diabetics [4]. The symptom
complex ofdiabetic gastroparesis has been cast in a minor role in the overall clinical
picture of diabetes, since it was overshadowed by the life-threatening complications
of the primary disease. It is becoming increasingly apparent, however, that altera-
tions in gastric motility can adversely and seriously affect control of the diabetes
[5,6].
Early investigators theorized that diabetic gastroparesis was due to a vagal
neuropathy, since symptoms were quite similar to those seen after vagotomy [4,5].
Other investigators subsequently made the interesting observation that changes in
gastric emptying which were assumed to reflect "autovagotomy" were not repro-
duced in non-diabetics by surgical vagotomy. There was increasing agreement that
the neuropathy was a result of the abnormal metabolism present in unregulated
diabetes. An inverse correlation was present between blood sugar levels and gastric
motility [6] and it was also noted that peripheral nerve conduction (and presumably
autonomic nerve conduction as well) was improved by adequate treatment of the
diabetic state. Animal studies showed that normoglycemia prevented and reversed
the accumulation ofincreased sugars at nerve endings and, in doing so, reversed the
attendant neuropathy. Recently, myoinosytol metabolism was invoked as a possible
important factor in the pathogenesis of diabetic gastroparesis and, indeed, in all of
the diabetic neuropathies [7]. This substance is important in lipid synthesis and is
essential for the integrity of the nerve unit. Urinary excretion of myoinosytol is
increased in diabetics who are under poor control but is reversed when a nor-
moglycemic state is attained. Structural changes have also been reported in the post-
ganglionic sympathetic fibers to the gastrointestinal tract, and these have been cor-
related with control of the underlying disease [8].
CLINICAL PICTURE
Incidence
There are approximately five million diabetics in the United States. Published in-
cidence figures on gastroparesis vary widely, and this variation reflects diagnostic
criteria, populations studied, etc. An earlier review in 1947 demonstrated that of 35
patients with peripheral neuropathy, five had signs of gastric retention [9].
Kassander found six cases ofgastric stasis in 27 consecutive diabetic admissions [4],
while Ferroir [2] diagnosed gastric stasis in 16 of 27 diabetics. In other published
reports, the incidence of gastric motor abnormalities has been reported to vary
from 20 to 30 percent [10] to only 35 of 44,000 in a Joslin clinic survey [11]. This
variation in reported incidence is explained by the different criteria which have been
used in the past to make the diagnosis, the well-known phenomenon that most
diabetics with gastroparesis are asymptomatic, and the recognized problems in the
quantitation of delayed gastric emptying by radiological techniques.
CLINICAL PRESENTATION
Signs and Symptoms
While an undetermined proportion of diabetics with slow emptying of food are
asymptomatic, the usual clinical manifestations, if present, are anorexia, nausea,
vomiting, abdominal pain, and a persistent fullness after meals. Acute episodes of
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gastric stasis symptomatology often accompany ketoacidosis or, less commonly,Qc-
cur after a period of "stress" in a non-acidotic diabetic. In case reports of chronic
diabetic gastroparesis [3,6,11], many patients have an intermittent course with some
symptom-free periods. After multiple relapses, chronic stasis may ensue. In general,
gastroparesis is not sex-related and occurs mostly in long-term diabetics, usually in
association with other neuropathies [11], particularly a peripheral neuropathy,
present clinically or by motor nerve conduction studies. Often other symptoms of
autonomic dysfunction, including neurogenic bladder, orthostatic hypotension, im-
potence, and gustatory sweating are present. Many of those with gastroparesis have
concomitant symptoms of diabetic colonic and small bowel dysfunction with con-
stipation and/or diarrhea. In addition, patients often exhibit the ravages of long-
standing diabetes, including impaired vision, renal failure sometimes requiring
dialysis, and peripheral vascular disease. Long-standing gastroparesis has been
associated with the formation of gastric bezoar. The other side of the gastroparesis
spectrum involves hypoglycemic tendencies. The presence of stasis has often
precluded the usual oral treatment for hypoglycemia. Furthermore, diabetic control
is based, in part, on the premise that food, when eaten as prescribed, can be op-
timally absorbed.
'RADIOLOGICAL MANIFESTATIONS
Conventional barium meal investigations, when positive, have revealed a dilated
stomach with impaired peristalsis, delayed gastric emptying, and retention of food
in the presence of a patulous pylorus [2,3]. These authors have cautioned that
changes in symptomatology do not correlate well with changes in the X-ray picture.
It was appreciated that radiological abnormalities of esophageal motility were
observed in some patients, usually with other evidence of an autonomic neuropathy.
Relying on the gastric emptying of barium during a standard upper gastrointestinal
series will result in a positive study only in severe cases of diabetic gastric stasis. The
majority ofpatients whose gastric emptying is slow using isotope-labeled solid meals
will have a normal barium result. The gastrointestinal series is important to define
normal gastric and duodenal anatomy by excluding peptic ulcer disease and
obstructing lesions or masses of the antrum, pylorus, or duodenum. Some previous
studies have suggested that the rate of gastric emptying can be clinically assessed
with the barium burger meal or with some other modification where solid food is
mixed with a barium meal. Here the effects of solids upon barium emptying are be-
ing studied. The marker, barium, is not fully attached to the meal and empties in-
dependently of the solid food particles. Furthermore, the information will be purely
qualitative and promotes extensive exposure to radiation.
Gamma Camera and Isotopic Techniques
Previous studies of gastric emptying using saline meals or a modified liquid test
meal have shown that emptying is often slower in diabetics. However, studies of
gastric emptying, based on the use of a liquid meal, are limited and, if normal, do
not mean that emptying ofa more natural meal is also normal. Scanning and gamma
camera methods, based on the incorporation of gamma-emitting radioactive
isotopes in food, offer a means of assessing gastric emptying after ingestion of or-
dinary meals, but the heterogeneity of such meals may present a problem, as liquids
and solids ingested together are not emptied from the stomach at the same rate
[12-15]. When an isotope marker of a meal is employed it is, therefore, necessary to
181SALTZMAN AND McCALLUM
define which component of the meal it represents. In most studies, the solid food
component ofthe meal is the one studied, but, with more sophisticated studies, dual
labeling with separate isotopes (usually Technetium and Indium) allows simul-
taneous assessment of solid and liquid gastric emptying rates. In a study of gastric
emptying using a scintiscanning technique, a marked delay in gastric emptying cor-
related well with the symptoms ofgastric stasis and was found more commonly than
with conventional radiology using barium.
Impaired gastric emptying of solid food is the first abnormality that occurs and
therefore this finding is the most sensitive indicator of diabetic-related effects on
gastric motility. Liquid emptying becomes delayed at a later time and reflects a more
severe involvement of smooth muscle function accompanying diabetes. Extensive
gastric emptying evaluations of diabetic patients with a peripheral neuropathy in a
clinic setting using radionuclide techniques have not been performed, but the
authors estimate that slow gastric emptying of solids may be detected in at least 75
percent of such a population. Many ofthese patients would not be symptomatic for
gastric stasis, but the impairment in gastric emptying may impact on day-to-day
glucose control and estimation of insulin dosage.
Clinical and experimental studies have suggested that the loss of normal vagal in-
nervation of the stomach results in accelerated early gastric emptying. Campbell et
al. [16] were unable to identify any rapid early emptying of the liquid marker cor-
responding to such a pattern. However, an unexpected finding in their patients
without gastric stasis was the loss of the solid-liquid differentition. It was implied
that the findings indicated that in diabetics without gastric stasis, there may be an
abnormality ofantral peristalsis for which the usual explanation of"autovagotomy"
is not appropriate.
The technique of radionuclide studies to evaluate gastric emptying is not beyond
the capability of most hospital nuclear medicine departments. A very convenient
meal that we have utilized is that employing a semi-solid meal consisting of an egg-
salad sandwich on white bread containing 500 microcuries of99mTechnetium-DTPA
FIG. 1. Upper gastrointestinal series and small
bowel follow-through in a 27-year-old juvenile-
onset diabetic showing retained barium in the
stomach at two hours with some barium also
reaching the cecum. The mechanical device at the
extreme left is an insulin pump which the patient
wears on her belt and which constantly infuses
insulin subcutaneously.
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NORMAL GASTRIC EMPTYING RESULT
( Isotope-Labeled Chicken Li Meal)
Anterior
Abdomino I
View At 120Min
FIG. 2. Normal gastric emptying
result after ingestion of an isotope-
labeled chicken-liver meal. Radio-
nuclide images of the stomach are
shown up to 120 minutes after the
meal. A full scan of the anterior
abdomen at the termination of the
study confirms isotope dispersed
throughout the small bowel, with less
than 50 percent remaining in the
stomach.
(diethylene-triamine-penta-acetic acid) soaked into the bread of the sandwich [17].
This can be ingested along with a small amount of skim milk. Once the normal
gastric emptying rate has been standardized using normal individuals, then ex-
trapolations can be made to diabetics and other clinical states.
Figure 1 is a radiograph obtained in a 27-year-old juvenile-onset diabetic with
gastric stasis symptoms showing barium in the stomach at two hours after its inges-
tion and with some gastric dilatation. Figure 2 shows a normal gastric emptying test,
using an isotope-labeled solid meal (chicken liver) technique. Emptying occurred
linearly over a two-hour period and, as can be appreciated by the final view of the
anterior abdomen, significant counts are present in the distal small bowel. Figure 3
shows a diabetic patient with symptoms consistent with gastric stasis and a normal
emptying on a previous barium study. There is almost complete retention of an
isotope-labeled chicken-liver meal two hours after its ingestion.
GASTRIC SCINTISCAN STUDY IN PATIENT
WITH DIABETIC GASTROPARESIS
(IsotopeLobeled Chiccken Liver Meol)
90 MIN 120MIN ANTERIOR
..: ...:.
ABDOMINA:
IMAGE: At
120 MIN
FIG. 3. Gastric emptying study in an insulin-
dependent diabetic with gastric retention symp-
toms utilizing an isotope-labeled chicken-liver
meal. The scintiscans show retention of isotope
in the stomach, and no isotope is appreciated in
the small bowel after 120 minutes.
12-0 Mi
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TREATMENT
It is important to re-emphasize that gastric stasis due to diabetes is partially a
diagnosis of exclusion. Standard diagnostic measures, as outlined, are necessary,
and of particular importance is the history of other drugs which may have induced
symptoms of gastric stasis or, indeed, slowed gastrointestinal motility. Most com-
mon offenders in this population are narcotic agents, which are often being taken
for the pain ofthe peripheral neuropathy, as well as various anticholinergics and an-
tidepressants. A standard upper gastrointestinal series, or upper gastrointestinal en-
doscopy, excludes obstruction of the distal stomach and duodenum without address-
ing the role of gastrointestinal motility necessarily. Isotope-labeled gastric emptying
studies complete the evaluation. Occasionally, the patient may need to be hospital-
ized because of advancing renal failure which may result in vomiting and confuse the
clinical picture, or for acute fluid and electrolyte repletion, as well as diabetic con-
trol. Sometimes a better control of blood glucose may be enough to enhance motility
toward normal in this type of setting which may be associated with intermittent
relapses of diabetic ketoacidosis.
As opposed to this intermittent setting is the more chronically suffering diabetic
gastric-stasis patient. Conventional antiemetic therapy is usually not helpful.
Previous approaches have been based on the use of the cholinergic agent
bethanechol. While its results were unpredictable, there have been some recent phar-
macological studies supporting a theoretical role for its use in diabetic gastric-stasis
patients [18]. The dose is titrated to relieve symptoms and minimize adverse reac-
tions. A recommended starting dose is 25 mg 15 to 30 minutes prior to meals and at
bedtime. In our experience, the result is erratic and not sustained.
At present, the most powerful and well-studied gastric prokinetic in diabetic
gastric-stasis syndromes is metoclopramide (methoxychloroprocanamide). This
drug, recently approved in this country, is now available orally for the indication of
diabetic gastric stasis. It appears to be a potent antiemetic acting centrally, as well as
a potent stimulant of upper gastrointestinal smooth muscle acting peripherally [19].
Its mechanism of action is probably threefold: (1) It potentiates acetylcholine
release and, therefore, promotes cholinergic effects on the musculature of the prox-
imal gut being blocked partially by atropine, but not by vagotomy. It has no effect
on gastric acid secretion or fasting serum gastrin. However, unlike conventional
cholinergic compounds, it may require some background of cholinergic activity,
and this may be the reason why its effects are unpredictable in long-standing diabetic
gastric-stasis patients. (2) It is a potent dopamine antagonist and, peripherally, op-
poses dopamine, an inhibitory neurotransmitter of gastrointestinal smooth muscle.
(3) The antiemetic properties of metoclopramide result from antagonism of central
dopamine receptors, as demonstrated by its ability to block the effect of apomor-
phine on the chemoreceptor trigger zone. Experience with metoclopramide in
treating patients with diabetic gastric stasis has shown that it is capable, both
parenterally and orally, of accelerating the delayed gastric emptying present in these
patients and returning it toward the rate present in normal volunteers [20]. This
can be demonstrated on a series of gastric scintiscans from an individual patient
(Fig. 4). The drug is most efficacious in decreasing feelings of epigastric fullness,
bloating, and pressure, along with nausea and vomiting and anorexia, resulting in
improved weight gain and a general sense of "feeling better" in these patients [20]
(Fig. 5). This latter effect may be partially centrally mediated.
Side effects are reported in between 10 and 20 percent of the patients, with the
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GASTRIC SCINTISCAN STUDIES IN DIABETIC GASTROPARESIS
(Employing Isotope Labeled Chicken Liver Meal)
A TER AFTER O.RAL
BASELINE STUDY MCLOPRA E
MIN
FIG. 4. A series ofgastric scintiscans obtained
START from a diabetic with symptomatic gastric stasis,
showing the baseline period, after receiving
parenteral metoclopramide (10 mg), and then
after a clinical trial of oral metoclopramide
60MIN therapy. The isotope-labeled chicken-liver
preparation is used on this particular occasion,
and it can be seen that the slowemptying present
U during the baseline improved with metoclo-
I2OMtIN pramide, both orally and parenterally, consis-
tent with the patient's clinical response while
receiving chronic metoclopramide therapy.
most common one being an increased feeling of restlessness and anxiety, which can
be improved by decreasing the dose. Other reactions related to its dopamine an-
tagonistic properties include extrapyramidally mediated dystonic reactions,
oculogyric crisis, and tremor. It also increases serum prolactin concentrations,
sometimes with breast enlargement and tenderness, galactorrhea, and/or amenor-
rhea.
Because metoclopramide does have some incidence of side effects, a new agent
has been developed and is being actively investigated in this country. It is a selective
peripheral dopamine antagonist called domperidone, with a wide safety margin.
Domperidone has been used successfully in Europe for a number of years and we
and others are currently investigating this drug in this country.
Many patients with gastroparesis have been subjected to various surgical drainage
METOCLOPRAMIDE AND PLACEBO TREATMENT
OF DIABETIC GASTRIC STASIS
I Basal Period
* Plocebo Treatment
* Metocopromide Treatment Period
Metoclopromide vs Placebo
*p<O.05 LUI
c
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FIG. 5. This figure shows
the results of a double-blind
clinical trial, in 13 patients
with diabetic gastric stasis
receiving metoclopramide
or placebo in a randomized,
double-blind crossover de-
sign where each patient re-
ceived drug and placebo for
three weeks. Metoclopram-
ide significantly improved
the patients' symptoms of
epigastric fullness, pressure
and bloating, nausea, vom-
iting, and anorexia, when
compared with the placebo
period.
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procedures as a "last resort." It is now accepted that surgery is rarely advisable [6]
and subjecting these very sick patients to unnecessary surgery is counterproductive
and increases their morbidity. One of the reasons for problems after a gastro-
jejunostomy and/or antrectomy is related to small bowel absorptive abnormalities
associated with the patient's visceral neuropathy. The absorptive capacity will be
overwhelmed by rapid gastric emptying post-operatively. The absorptive state is
already borderline because of impaired motility and bacterial overgrowth. A possi-
ble consideration in a severe case is the insertion of a feeding jejunostomy under
local anesthesia to sustain adequate nutrition. Another alternative is per oral place-
ment of thin duodenal and jejunal feeding tubes. Feeding with these latter two
methods involves the use of a continuous infusion technique using Ensure or
another nutritional caloric liquid. This technique is more physiologic and overcomes
the malabsorption and/or diarrhea related to bolus ingestions.
DIABETES MELLITUS AND GASTRIC ACID SECRETION
Gastric atrophy, often with parietal cell antibodies, is common in diabetics, and
the frequency of pernicious anemia with its expected intrinsic factor antibodies is
also increased. These abnormalities are most common in insulin-dependent
diabetics. In 200 insulin-dependent diabetic patients, the prevalence of parietal cell
antibodies was 28 percent, whereas in 200 diabetics not requiring insulin, the
prevalence was 14 percent, and in controls it was only 11 percent. The prevalence of
pernicious anemia with intrinsic factor antibodies was 4 percent in the insulin-
dependent group, but pernicious anemia was not detected in patients who did not re-
quire insulin [21].
The frequency of peptic ulcer disease is reduced in diabetics because of a number
of contributing factors. Gastric analysis has given conflicting results but generally
suggests that long-standing diabetics have lower acid levels than normals, possibly
secondary to vagal neuropathy [22]. Fluctuating metabolic events, such as
hyperglycemia and hyperglucagonemia, both ofwhich inhibit gastric acid, might ac-
count for the inconsistent results, but it seems likely that the contribution of other
peptide hormones may be equally important. For example, gastric inhibitory pep-
tide, an enteric hormone that inhibits gastric acid secretion and stimulates insulin in
response to glucose, is released in diabetic patients given oral glucose and may con-
tribute to the low acid levels in the same diabetics [23].
SUMMARY
We have tried to summarize the spectrum of abnormalities that can affect the
stomach ofdiabetic patients. Emphasis is particularly placed on the recent advances
in the understanding of gastrointestinal smooth muscle function and, in particular,
the way in which the stomach handles solids and liquids. This has allowed improve-
ment in diagnostic tests for gastric emptying disturbances utilizing the role of iso-
tope-labeled test meals, both solid and liquid. This advance in diagnostic accuracy
has allowed a better appreciation of the spectrum of gastric emptying disturbances
that can be expected in the diabetic population. The other important advance has
been the development of the dopamine antagonist metoclopramide, which through
its pro-kinetic and anti-emetic properties is a valuable adjunct in the therapy of
gastric stasis due to diabetes mellitus.
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